Press Enter to search · Esc to close
A new post-hoc analysis tracks inflammatory and immune markers in adults with type 2 diabetes for two years on a carb-restricted, ketogenic plan — and the signal goes well beyond blood sugar.
A once-daily oral GLP-1, fresh data linking the class to lower lumbar disease risk, and a network meta-analysis hinting at a nuanced colorectal cancer question. Here's what the moderate evidence actually says.
Once a niche tool for type 1 diabetes, continuous glucose monitors are quietly reshaping how doctors — and families — read the body's signals in real time.
A new review reframes Alzheimer's risk around peripheral insulin resistance — not blood sugar itself — and points to tiny cellular couriers as possible carriers of metabolic damage to the brain.
A wave of head-to-head trials and a biased-agonist newcomer show the GLP-1 class is fragmenting into distinct molecules with measurably different profiles.
A 26-week Phase 2 trial pits a once-daily oral non-peptide against dulaglutide — and the β-cell and insulin-sensitivity signals are hard to ignore.
Three new human studies — a decade-long cohort, a systematic review, and a biomarker case-control trial — sketch an emerging toolkit for spotting dysglycemia before it hardens into disease.
Microbiota-targeted therapies, a newly mapped liver enzyme called HYAL1, and Mendelian evidence linking metabolic syndrome to IBD are quietly reshaping how scientists think about type 2 diabetes.
Fresh cohort analyses say the perioperative picture is procedure-specific — reassuring at the hip, worrying at the shoulder — and shortages keep complicating the calculus.
The world's most common chronic liver disease just got a new name. The bigger shift: doctors now treat it as a cardiometabolic problem, because most patients die of heart disease, not cirrhosis.